Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03824275
Recruitment Status : Recruiting
First Posted : January 31, 2019
Last Update Posted : June 25, 2019
Sponsor:
Information provided by (Responsible Party):
Emerson Lim, Columbia University

Brief Summary:
PyL, also known as [18F]DCFPyL, is a second-generation fluorinated prostate-specific membrane antigen (PSMA) targeted PET imaging agent. In preliminary studies it demonstrates a higher detection of metastatic prostate lesions compared to standard imaging. Its ability to image metastatic prostate cancer sites was comparable to 68Ga-PSMA with high tumor-to-background ratios.Additionally, [18F] PyL demonstrated higher mean tumor-to-background ratios when using kidney, spleen, or parotid as reference organs. However, the role of [18F] PyL in tumor response to therapy has not been evaluated, specifically the potential to serve as a predictive biomarker of response. Given the high cost of current therapeutic agents in mCRPC, there is a need for an early response biomarker to stratify which patients will benefit from therapy and which will not. This will also allow for earlier change in management of patients who will not response to these therapies, potentially improving patient outcomes.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Drug: 18F- DCFPyL PET/CT Phase 2 Phase 3

Detailed Description:

The investigators will conduct a prospective phase II/III study of 300 men diagnosed with prostate cancer with a rising prostate-specific antigen (PSA). Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations and undergo 18F- DCFPyL PET/CT.

[18F]DCFPyL will be used for study imaging.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective, non-randomized
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: 18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Actual Study Start Date : February 12, 2019
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 18F- DCFPyL PET/CT
Upon enrollment, subjects will undergo standard of care imaging (defined as a CT or MRI of the chest, abdomen, and pelvis, and 99mTc bone scans) if not obtained within 45 days of enrollment. Subjects will have standard of care laboratory evaluations including complete blood count (CBC), serum chemistries, hepatic panel, lactate dehydrogenase (LDH), and PSA. Liquid biopsies for circulating tumor DNA (ctDNA) and exosome analysis will occur at the same time. Subjects will then undergo 18F- DCFPyL PET/CT.
Drug: 18F- DCFPyL PET/CT
A CT scan using a radioactive marker to better image tumors
Other Name: CT scan




Primary Outcome Measures :
  1. To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis [ Time Frame: 3.5 years ]
    To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-patient basis


Secondary Outcome Measures :
  1. To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-region basis, with regions being the prostate or prostate bed, pelvis, extra pelvis, and bones [ Time Frame: 3.5 years ]
    To determine the positive predictive value of 18F-DCFPyL PET/CT on a per-region basis

  2. To determine the sensitivity and specificity of 18F-DCFPyL PET/CT on a per patient and region basis [ Time Frame: 3.5 years ]
    To determine the sensitivity and specificity of 18F-DCFPyL PET/CT on a per patient and region basis


Other Outcome Measures:
  1. To characterize ctDNA and exosomes in patients with prostate cancer [ Time Frame: 3.5 years ]
    To characterize ctDNA and exosomes in patients with prostate cancer

  2. To determine correlation with ctDNA and/or exosome levels with disease burden [ Time Frame: 3.5 years ]
    To determine correlation with ctDNA and/or exosome levels with disease burden



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed diagnosis of prostate cancer
  2. PSA ≥ 0.2ng/ml
  3. Age ≥ 18 years of age
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (karnofsky ≥ 60%)
  5. Ability to understand and willingness to sign a written informed consent document
  6. Wiling to comply with clinical trial instructions and requirements
  7. Willing to cover the cost of PyL PET/CT imaging if funds are not available

Exclusion Criteria:

  1. History of another active malignancy within 3 years, other than basal cell and squamous cell carcinoma of the skin
  2. Presence of prostate brachytherapy implants unless approved by the PI
  3. Administration of another radioisotope within five physical half-lives of trial enrollment
  4. Radiation or chemotherapy within 2 weeks prior to trial enrollment
  5. Serum creatinine > 3 times the upper limit of normal
  6. Serum total bilirubin > 3 times the upper limit of normal
  7. Aspartate transaminase (AST) or alanine aminotransferase (ALT) >5 times the upper limit of normal
  8. Inadequate venous access

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03824275


Contacts
Layout table for location contacts
Contact: Lisa Olmos, RN 212-342-5162 cancerclinicaltrials@cumc.columbia.edu
Contact: Ana Serra 212-304-5558 as5713@cumc.columbia.edu

Locations
Layout table for location information
United States, New York
Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Ana Serra       as5713@cumc.columbia.edu   
Principal Investigator: Emerson Lim, MD         
Sponsors and Collaborators
Columbia University
Investigators
Layout table for investigator information
Principal Investigator: Emerson Lim, MD Assistant Professor of Medicine

Layout table for additonal information
Responsible Party: Emerson Lim, Associate Clinical Professor of Medicine, Columbia University
ClinicalTrials.gov Identifier: NCT03824275     History of Changes
Other Study ID Numbers: AAAS1862
First Posted: January 31, 2019    Key Record Dates
Last Update Posted: June 25, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases